Navigation Links
Denver-Ft. Collins Ophthalmologist First in Colorado to Implant nanoFLEX Lens
Date:10/27/2009

DENVER, Oct. 27 /PRNewswire/ -- A Denver ophthalmologist recently became the first in Colorado to implant a special type of lens during cataract surgery, raising the bar for patient care in the state while increasing the quality of life for his patients.

Dr. Paul Cutarelli, director of Cutarelli Vision in Denver and Fort Collins, said he implanted an advanced nanoFLEX lens in October in the eye of a 70-year-old man whose cataracts in his left eye were so bad he couldn't read any more. Manufactured by STAAR Surgical, the revolutionary lens offers better quality of vision at night, filters ultraviolet light and is made of a high-tech material so close to the human lens that it's easily tolerated by the eye, greatly lowering inflammation complications.

His patient was a retiree who didn't want to lose his active lifestyle, one that includes riding his Harley with his girlfriend, Cutarelli said.

"He waited until I got on his insurance plan," Cutarelli said. "He didn't want anyone else to do the cataract surgery and wanted to have good reading vision in that eye."

The procedure in the patient's left eye took about 10 minutes, during which Cutarelli removed the bad lens and replaced it with the implant.

Just a few hours later, the patient called the doctor from home and told him he could read clearly and saw better out of his left eye than his right one.

The news was part of what makes the doctor's work so rewarding. And the special lens has a very high patient satisfaction rate, he said.

"It's fantastic to work with patients like this because I can help them stay active. This is a quality of life issue. Without this lens, this guy wouldn't be able to live the full life that he enjoys."

The procedure is just one of many "firsts" for Cutarelli in Colorado. He also was the first to use the lens in northern Colorado at his Fort Collins practice. That surgery also took place in October. His patient is a Wal-Mart greeter whose vision is now 20/20 and saw vibrant colors for the first time in many years.

He was also the first to use Intacs to fight keratoconus, a disease that causes debilitating astigmatisms and fluctuating vision problems in patients. Intacs are plastic rings implanted under the eye's outer most layer, the cornea, and correct its distorted shape caused by pressure problems associated with the disease.

Cutarelli has also done a great deal of published research, always staying abreast of the newest trends and technologies in vision correction. He was a coinvestigator during more than 15 FDA clinical trials for excimer lasers, the biggest developments in laser vision surgery to appear in the last decade. His work has also appeared in numerous scientific publications reviewed by his peers, including Ophthalmology and Current Eye Research, as well as several book chapters on laser eye surgery.

An expert in correcting refractive and presbyopic problems, Cutarelli has performed more than 60,000 LASIK and LASEK procedures in Colorado. He's one of only a few who've had one-year fellowships in refractive and corneal surgeries, including transplants, and is certified by the American Board of Ophthalmology.

Before he opened his practice in Denver, Cutarelli directed refractive surgery and was an assistant ophthalmology professor at University Hospitals in Cleveland, Ohio. There, he founded the hospitals' refractive surgery fellowship training program. And he taught medical students at his alma mater, Case Western Reserve University.

His expertise has been sought after internationally, at London's Moorfields Eye Hospital and the Al Noor Hospital in the United Arab Emirates.

www.denverlasik.com

www.fortcollinsvision.com

Source: Cutarelli Vision

    CONTACT:
    Cutarelli Vision
    7887 E Belleview Ave
    Denver (Englewood), CO    80111
    (303) 486-2020   

SOURCE Cutarelli Vision


'/>"/>
SOURCE Cutarelli Vision
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016  EIP ... it has obtained proof-of-mechanism for neflamapimod (previously code ... completed Phase 2a clinical trials that demonstrated significant ... Study 302 (12-week treatment) and Study 303 (6-week ... Clinical Trials in Alzheimer,s Disease (CTAD) scientific conference ...
Breaking Medicine Technology:
(Date:12/10/2016)... WASHINGTON, D.C. (PRWEB) , ... December 10, 2016 ... ... children’s Christmas wish lists for Santa are all sources of external stimuli that ... season. For some, the added pressure to spread holiday cheer through gifts, food ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... aural rehabilitation—provided by audiologists—to remain a critical part of public access to hearing ... Administration (FDA) announced this week that, starting immediately, it would no ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund ... (NCADD) is recommending the film Whispering Spirits and its discussion guide for ... as an education tool in the war against teen drug abuse. NCADD is ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of ... a new solution for Emergency Departments (ED) has been added to their portfolio. ... Department examination rooms, and with a simplified pallet of information available to the ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
Breaking Medicine News(10 mins):